

Screening for Visual Impairment in Children Younger than Age 5 Years

Recommendation Statement

U.S. Preventive Services Task Force

This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for visual impairment in children younger than age 5 years and the supporting scientific evidence, and updates the 1996 recommendations contained in the *Guide to Clinical Preventive Services*, second edition.¹ In 1996, the USPSTF recommended vision screening for amblyopia and strabismus for all children once before entering school (B recommendation).¹ Since then, the USPSTF criteria to rate the strength of the evidence have changed.² Therefore, this recommendation statement has been updated and revised based on the current USPSTF methodology and rating of the strength of the evidence. Explanations of the current Task Force ratings and of the strength of overall evidence are given in Appendix A and Appendix B, respectively.

The complete information on which this statement is based, including evidence tables and references, is available in the Systematic Evidence Review³ and in the update of the evidence⁴ on this topic, on the USPSTF Web site (www.preventiveservices.ahrq.gov). The recommendation statement and update of the evidence are also available in print from the Agency for Healthcare Research and Quality (AHRQ) Publications Clearinghouse (call 1-800-358-9295, or e-mail ahrqpubs@ahrq.gov). The recommendation is also posted on the Web site of the National Guideline Clearinghouse™ (www.guideline.gov).

Recommendations made by the USPSTF are independent of the U.S. Government. They should not be construed as an official position of AHRQ or the U.S. Department of Health and Human Services.

This recommendation statement was first published in *Ann Fam Med*. 2004;2:263–266.

Summary of Recommendation

The USPSTF recommends screening to detect amblyopia, strabismus, and defects in visual acuity in children younger than age 5 years.

B recommendation.

The USPSTF found no direct evidence that screening for visual impairment in children leads to improved visual acuity. However, the USPSTF found fair evidence that screening tests have reasonable accuracy in identifying strabismus, amblyopia, and refractive error in children with these conditions; that more intensive screening compared with usual screening leads to improved visual acuity; and that treatment of strabismus and amblyopia can improve visual acuity and reduce long-term amblyopia. The USPSTF found no evidence for harms of screening, judged the potential for harms to be small, and concluded that the benefits of screening are likely to outweigh any potential harms.

Clinical Considerations

- The most common causes of visual impairment in children are: (1) amblyopia and its risk factors and (2) refractive error not associated with amblyopia. Amblyopia refers to reduced visual acuity without a detectable organic lesion of the eye and is usually associated with amblyogenic risk factors that interfere with normal binocular vision, such as strabismus (ocular misalignment), anisometropia (a large difference in refractive power between the 2 eyes), cataract (lens opacity),

Corresponding Author: Ned Calonge, MD, MPH, Chair, U.S. Preventive Services Task Force, c/o Program Director, USPSTF, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, e-mail: uspstf@ahrq.gov.

and ptosis (eyelid drooping). Refractive error not associated with amblyopia principally includes myopia (nearsightedness) and hyperopia (farsightedness); both remain correctable regardless of the age at detection.

- Various tests are used widely in the United States to identify visual defects in children, and the choice of tests is influenced by the child's age. During the first year of life, strabismus can be assessed by the cover test and the Hirschberg light reflex test. Screening children younger than age 3 years for visual acuity is more challenging than screening older children and typically requires testing by specially trained personnel. Newer automated techniques can be used to test these children. Photoscreening can detect amblyogenic risk factors such as strabismus, significant refractive error, and media opacities; however, photoscreening cannot detect amblyopia.
- Traditional vision testing requires a cooperative, verbal child and cannot be performed reliably until ages 3 to 4 years. In children older than age 3 years, stereopsis (the ability of both eyes to function together) can be assessed with the Random Dot E test or Titmus Fly Stereotest; visual acuity can be assessed by tests such as the HOTV chart, Lea symbols, or the tumbling E. Some of these tests have better test characteristics than others.
- Based on their review of current evidence, the USPSTF was unable to determine the optimal screening tests, periodicity of screening, or technical proficiency required of the screening clinician. Based on expert opinion, the American Academy of Pediatrics (AAP) recommends the following vision screening be performed at all well-child visits for children starting in the newborn period to 3 years: ocular history, vision assessment, external inspection of the eyes and lids, ocular motility assessment, pupil examination, and red reflex examination. For children aged 3 to 5 years, the AAP recommends the aforementioned screening in addition to age-appropriate visual acuity measurement (using HOTV or tumbling E tests) and ophthalmoscopy.⁵

- The USPSTF found that early detection and treatment of amblyopia and amblyogenic risk factors can improve visual acuity. These treatments include surgery for strabismus and cataracts; use of glasses, contact lenses, or refractive surgery treatments to correct refractive error; and visual training, patching, or atropine therapy of the nonamblyopic eye to treat amblyopia.
- These recommendations do not address screening for other anatomic or pathologic entities, such as macro cornea, cataracts, retinal abnormalities, or neonatal neuroblastoma, nor do they address newer screening technologies currently under investigation.

Discussion

Visual impairment caused by refractive error, amblyopia, strabismus, and astigmatism is a common condition among young children, affecting 5% to 10% of all preschoolers. Amblyopia is present in 1% to 4% of preschool children; an estimated 5% to 7% of preschool children have refractive errors.⁴ Uncorrected amblyopia may harm school performance, ability to learn, and later, adult self-image.⁶ Furthermore, uncorrected amblyopia may be a risk factor for future total blindness. Because visual impairment in children is common and believed to have an early sensitive period when interventions lead to better outcomes, much interest has focused on primary care vision-screening tools for early detection, referral, and treatment.

The USPSTF found no direct evidence that screening for visual impairment, compared with no screening, leads to improved visual acuity. However, the USPSTF found 1 fair quality study showing that intense screening by eye professionals (compared with usual screening) decreases the prevalence of amblyopia.⁷ This recent randomized controlled trial in the United Kingdom, the Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC) trial,⁷ has reported that intensive screening performed 6 times between ages 8 and 37 months (using the cover test, Cardiff Cards, Kay Picture test, and HOTV letters by an eye professional) led to decreased prevalence of amblyopia and improved visual acuity compared with a one-time visual

screening at age 37 months (using the Kay Picture test and HOTV letters). Any child failing a screening test was referred to the hospital eye service for further testing and treatment. Compared with the group screened once at age 37 months, the intensively screened group had a significantly lower prevalence of severe amblyopia at age 7.5 years (amblyopia B prevalence = 0.6% vs 1.8%) and a lower prevalence of residual amblyopia after treatment (7.5% vs 25%).

The USPSTF reviewed the evidence for the accuracy of vision screening tests in children younger than age 5 years. The USPSTF found no evidence evaluating the role of screening for family history or parental concern, or evaluating the accuracy of the clinical examination to detect visual impairments such as cataracts or strabismus. One fair quality study of children aged 3 to 5 years screened by public health nurses with annual tests, including Cambridge Crowding Cards, the Hirschberg test, and the Titmus Fly Stereotest, reported an overall sensitivity of 60% to 71% and a specificity of 70% to 80%.⁸ A good quality systematic review, evaluating the accuracy of the Snellen E test or Stycar graded balls and the Titmus Fly Stereotest in children aged 3 to 5 years, reported an estimated sensitivity of 9% to 12.5% and a specificity of 99%.⁹ Three poor quality studies examined the accuracy of the Medical Technology Incorporated (MTI) photoscreenerTM in a population of children younger than age 3 years with a high prevalence of visual impairment. Sensitivity ranged from 37% to 88%, and specificity ranged from 40% to 88%.¹⁰⁻¹² For the VisiscreenTM in children younger than age 3 years, overall sensitivity and specificity were 85% and 94%, respectively.¹³

The USPSTF found fair quality evidence that early treatment of amblyogenic risk factors, including strabismus, refractive error, and cataracts, prevents amblyopia.¹⁴⁻¹⁷ Indirect evidence for the effectiveness of amblyopia treatment comes from cross-sectional studies that show lower prevalence of visual impairment in screened populations compared with unscreened populations.^{18,19} Cohort studies show that among children who have been diagnosed with visual impairment, amblyopia is unlikely to improve without therapy.²⁰ Both prospective and retrospective studies report that approximately 40% and 95% of persons with amblyopia have improved visual acuity

after treatment.²¹⁻³³ Two fair quality studies of treatment for amblyopia have found that successful outcomes depend on earlier treatment.^{24,31} In these studies, treatment efficacy steadily decreased after age 3 years; by age 12 years, treatment was ineffective. However, there is fair evidence to suggest that a modest delay in treatment does not harm outcomes.³⁴ Since the USPSTF found no studies that followed patients into adulthood, the long-term effectiveness of the interventions for amblyopia is unclear.

The USPSTF found no studies detailing permanent harms resulting from screening or data regarding the harms of false-positive screening. However, potential harms of screening may include “labeling” and the costs associated with the further evaluation of children with false-positive screening results. Potential harms of interventions include disruption of normal eye development and temporary loss of visual acuity of the nonamblyopic eye, which resolves weeks after completion of therapy.³⁵

There is limited research regarding the performance of vision screening tests in the primary care setting, although there are studies currently underway comparing various screening methods.³⁶⁻³⁸ Current studies reviewed by the USPSTF, including the ALSPAC study,⁷ support the effectiveness of intensive screening; however, it is not clear whether the magnitude of benefit observed in the United Kingdom study is generalizable to the United States population, to children younger than age 3 years, or to services provided by primary care clinicians. It would be helpful if similar studies comparing early intensive screening to usual visual screening were performed in children younger than age 5 years using screening tests commonly performed in the United States by primary care clinicians.

Recommendations of Other Groups

The recommendation of the American Academy of Family Physicians can be accessed at www.aafp.org/x7661.xml. The joint recommendation of the American Academy of Pediatrics, American Association for Pediatric Ophthalmology and Strabismus, and the

American Academy of Ophthalmology, can be accessed at <http://aap.org/policy/s0208.html>.

The clinical practice guideline of the American Optometric Association can be accessed at www.aoa.org/eweb/Documents/CPG-2.pdf. The recommendation of the Canadian Task Force on the Periodic Health Examination can be accessed at www.ctfphc.org.

References

1. U.S. Preventive Services Task Force. *Guide to Clinical Preventive Services*. 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1996.
2. Harris RP, Helfand M, Woolf SH, et al; Methods Work Group, Third U.S. Preventive Services Task Force. Current methods of the U.S. Preventive Services Task Force: a review of the process. *Am J Prev Med*. 2001;20(3S):21–35.
3. Kemper A, Harris R, Lieu TA, Homer CJ, Whitener BL. *Screening for Visual Impairment in Children Younger than Age 5 Years*. Systematic Evidence Review No. 27 (Prepared by the Research Triangle Institute—University of North Carolina Evidence-based Practice Center under Contract No. 290-97-0011). Rockville, MD: Agency for Healthcare Research and Quality. May 2004. (Available on the AHRQ Web site at: www.ahrq.gov/clinic/serfiles.htm.)
4. Nelson H, Nygren P, Huffman L, et al. Screening for visual impairment in children younger than age 5 years: update of the evidence from randomized controlled trials, 1999–2003, for the U.S. Preventive Services Task Force. May 2004. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.ahrq.gov/clinic/3rduspstf/visionscr/vischup.htm.
5. American Academy of Pediatrics Committee on Practice and Ambulatory Medicine and Section on Ophthalmology, American Association of Certified Orthoptists, American Association of Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology. Eye examination in infants, children, and young adults by pediatricians: policy statement. *Pediatrics*. 2003;111(4):902–907.
6. Packwood EA, Cruz OA, Rychwalski PJ, Keech RV. The psychosocial effects of amblyopia study. *J AAPOS*. 1999;3:15–17.
7. Williams C, Harrad RA, Harvey I, Sparrow JM. Screening for amblyopia in preschool children: results of a population-based, randomized controlled trial. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. *Ophthalmic Epidemiol*. 2001;8(5):279–295.
8. Robinson B, Bobier WR, Martin E, Bryant L. Measurement of the validity of a preschool vision screening program. *Am J Public Health*. 1999; 89:193–198.
9. Kennedy R, Sheps SB, Bagaric D. Field trial of the Otago photoscreener. *Can J Ophthalmol*. 1995; 30:193–197.
10. Tong PY, Enke-Miyazaki E, Bassin RE, et al. Screening for amblyopia in preverbal children with photoscreening photographs. National Children's Eye Care Foundation Vision Screening Study Group. *Ophthalmol*. 1998;105:856–863.
11. Tong PY, Bassin RE, Enke-Miyazaki E, et al. Screening for amblyopia in preverbal children with photoscreening photographs II. Sensitivity and specificity of the MTI Photoscreener. *Ophthalmol*. 2000;107:1623–1629.
12. Cooper CD, Gole GA, Hall JE, Colville DJ, Carden SM, Bowling FG. Evaluating photoscreeners II: MTI and Fortune. *Aust NZ J Ophthalmol*. 1999; 27:387–398.
13. Cogen MS, Ottemiller DE. Photorefractor for detection of treatable eye disorders in preverbal children. *Ala Med*. 1992;62:16–20.
14. Birch EE, Fawcett S, Stager DR. Why does early surgical alignment improve stereoacuity outcomes in infantile esotropia? *J AAPOS*. 2000;4:10–14.
15. Ingram RM, Arnold PE, Dally S, Lucas J. Results of a randomised trial of treating abnormal hypermetropia from the age of 6 months. *Br J Ophthalmol*. 1990;74:158–159.
16. Atkinson J, Braddick O, Robier B, et al. Two infant vision screening programmes: prediction and prevention of strabismus and amblyopia from photo- and videorefractive screening. *Eye*. 1996;10(Pt 2) 189–198.
17. Cheng KP, Hiles DA, Biglan AW, Pettapiece MC. Visual results after early surgical treatment of unilateral congenital cataracts. *Ophthalmol*. 1991; 98:903–910.

18. Jakobsson P, Kvarnstrom G, Lennerstrand G. Amblyopia in Sweden: Effects of screening at health care centers and in school. In: Spiritus M. Transactions, 23rd Meeting of the European Strabismological Association. New York, NY: Aeolus Press; 1997:25–30.
19. Eibschitz-Tsimhoni M, Friedman T, Naor J, Eibschitz N, Friedman Z. Early screening for amblyogenic risk factors lowers the prevalence and severity of amblyopia. *J AAPOS*. 2000;4:194–199.
20. Preslan MW, Novak A. Baltimore Vision Screening Project. Phase 2. *Ophthalmol*. 1998;105:150–153.
21. Eustis HS, Chamberlain D. Treatment for amblyopia: results using occlusive contact lens. *J Pediatr Ophthalmol*. 1996;33:319–322.
22. Krumholtz I, FitzGerald D. Efficacy of treatment modalities in refractive amblyopia. *J Am Optom Assoc*. 1999;70:399–404.
23. Bowman RJ, Williamson TH, Andrews RG, Aitchison TC, Dutton GN. An inner city preschool visual screening programme: long-term visual results. *Br J Ophthalmol*. 1998;82:543–548.
24. Latvala ML, Paloheimo M, Karma A. Screening of amblyopic children and long-term follow-up. *Acta Ophthalmol Scand*. 1996;74:488–492.
25. Beardsell R, Clarke S, Hill M. Outcome of occlusion treatment for amblyopia. *J Pediatr Ophthalmol*. 1999;36:19–24.
26. Hiscox F, Strong N, Thompson JR, Minshull C, Woodruff G. Occlusion for amblyopia: a comprehensive survey of outcome. *Eye*. 1992; 6:300–304.
27. Woodruff G, Hiscox F, Thompson JR, Smith LK. Factors affecting the outcome of children treated for amblyopia. *Eye*. 1994;8:627–631.
28. Newman DK, Hitchcock A, McCarthy H, Keast-Butler J, Moore AT. Preschool vision screening: outcome of children referred to the hospital eye service. *Br J Ophthalmol*. 1996;80:1077–1082.
29. Repka MX, Ray JM. The efficacy of optical and pharmacological penalization. *Ophthalmol*. 1993; 100:769–774.
30. Rutstein RP, Fuhr PS. Efficacy and stability of amblyopia therapy. *Optom Vis Sci*. 1992;69:747–754.
31. Epelbaum M, Milleret C, Buisseret P, Dufier JR. The sensitive period for strabismic amblyopia in humans. *Ophthalmol*. 1993;100:323–327.
32. Simons K, Stein L, Sener EC, Vitale S, Guyton DL. Full-time atropine, intermittent atropine, and optical penalization and binocular outcome in treatment of strabismic amblyopia. *Ophthalmol*. 1997; 104:2143–2155.
33. Bradford GM, Kutschke PJ, Scott WE. Results of amblyopia therapy in eyes with unilateral structural abnormalities. *Ophthalmol*. 1992;99:1616–1621.
34. Clarke MP, Wright CM, Hrisos S, Anderson JD, Henderson J, Richardson SR. Randomised controlled trial of treatment of unilateral visual impairment detected at preschool vision screening. *BMJ*. 2003;327:1251–1255.
35. Pediatric Eye Disease Investigator Group. A randomized trial of atropine versus patching for treatment of moderate amblyopia in children. *Arch Ophthalmol*. 2002;120:268–278.
36. Ciner EB, Schmidt PP, Orel-Bixler D, et al. Vision screening of preschool children: Evaluating the past, looking toward the future. *Optom Vis Sci*. 1998; 75:571–584.
37. Vision In Preschoolers Study (VIP Study) (2003). Available at: <http://www.nei.nih.gov/neitrials/static/study85.asp>. Accessed December 30, 2003.
38. Sunnah K, Project Manager, Project Universal Preschool Vision Screening (PUPVS), June 30, 2003, personal communication. Available at: <http://www.medicalhomeinfo.org/screening/vision.html>. Accessed December 30, 2003.

**Appendix A
U.S. Preventive Services Task Force—Recommendations and Ratings**

The Task Force grades its recommendations according to one of 5 classifications (A, B, C, D, I) reflecting the strength of evidence and magnitude of net benefit (benefits minus harms):

- A. The USPSTF strongly recommends that clinicians provide [the service] to eligible patients. *The USPSTF found good evidence that [the service] improves important health outcomes and concludes that benefits substantially outweigh harms.*
- B. The USPSTF recommends that clinicians provide [the service] to eligible patients. *The USPSTF found at least fair evidence that [the service] improves important health outcomes and concludes that benefits outweigh harms.*
- C. The USPSTF makes no recommendation for or against routine provision of [the service]. *The USPSTF found at least fair evidence that [the service] can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.*
- D. The USPSTF recommends against routinely providing [the service] to asymptomatic patients. *The USPSTF found at least fair evidence that [the service] is ineffective or that harms outweigh benefits.*
- I. The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing [the service]. *Evidence that [the service] is effective is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.*

**Appendix B
U.S. Preventive Services Task Force—Strength of Overall Evidence**

The USPSTF grades the quality of the overall evidence for a service on a 3-point scale (good, fair, poor):

- Good:** Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.
- Fair:** Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.
- Poor:** Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.

Members of the U.S. Preventive Services Task Force*

Alfred O. Berg, MD, MPH, Chair, USPSTF (Professor and Chair, Department of Family Medicine, University of Washington, Seattle, WA)
Janet D. Allan, PhD, RN, CS, Vice-chair, USPSTF (Dean, School of Nursing, University of Maryland, Baltimore, Baltimore, MD)
Ned Calonge, MD, MPH (Acting Chief Medical Officer and State Epidemiologist, Colorado Department of Public Health and Environment, Denver, CO)
Paul S. Frame, MD (Family Physician, Tri-County Family Medicine, Cohocton, NY, and Clinical Professor of Family Medicine, University of Rochester, Rochester, NY)
Joxel Garcia, MD, MBA (Deputy Director, Pan American Health Organization, Washington, DC)

Russell Harris, MD, MPH (Associate Professor of Medicine, Sheps Center for Health Services Research, University of North Carolina School of Medicine, Chapel Hill, NC)
Mark S. Johnson, MD, MPH (Professor and Chair, Department of Family Medicine, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark, NJ)
Jonathan D. Klein, MD, MPH (Associate Professor, Department of Pediatrics, University of Rochester School of Medicine, Rochester, NY)
Carol Loveland-Cherry, PhD, RN (Executive Associate Dean, School of Nursing, University of Michigan, Ann Arbor, MI)

Virginia A. Moyer, MD, MPH (Professor, Department of Pediatrics, University of Texas Health Science Center, Houston, TX)
C. Tracy Orleans, PhD (Senior Scientist, The Robert Wood Johnson Foundation, Princeton, NJ)
Albert L. Siu, MD, MSPH (Professor and Chairman, Brookdale Department of Geriatrics and Adult Development, Mount Sinai Medical Center, New York, NY)
Steven M. Teutsch, MD, MPH (Executive Director, Outcomes Research and Management, Merck & Company, Inc., West Point, PA)

Carolyn Westhoff, MD, MSc (Professor of Obstetrics and Gynecology and Professor of Public Health, Columbia University, New York, NY)
Steven H. Woolf, MD, MPH (Professor, Department of Family Practice and Department of Preventive and Community Medicine, and Director of Research, Department of Family Practice, Virginia Commonwealth University, Fairfax, VA)

*Members of the Task Force at the time this recommendation was finalized. For a list of current Task Force members, go to www.ahrq.gov/clinic/uspstfab.htm.